← Leaderboards

Darrell J Irvine

Icahn School Of Medicine At Mount Sinai

Google Scholar ↗PubMed ↗ORCID ↗

$37,519,809

Attributed

$60,233,872

Total exposure

36

Grants

27

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $9.6M · FY2005–25

$10M$7.5M$5M$2.5M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$60,233,872 · 36

By mechanism

R01$33,716,102 · 17

U01$7,391,285 · 2

P01$5,226,770 · 4

R37$4,431,323 · 1

R33$2,498,208 · 1

R61$2,349,037 · 1

Top collaborators

Shane P Crotty15 shared
Ron Weiss10 shared
Yizhou Dong9 shared
R. Brad Jones8 shared
Paula T Hammond6 shared
Mark Bathe4 shared
Manuel Garber4 shared
John E Harris4 shared

Others in their field

Top investigators on “Cells”

Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
Barton F Haynes · Duke University$457,457,619
David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
Dennis R. Burton · Scripps Research Institute$278,781,854
Mary M Horowitz · Medical College Of Wisconsin$237,383,608

Research focus

CellsResponseIn VivoAntigensDesignVaccinesImmune ResponseVaccinationT-LymphocyteAdjuvantTechnologyNanoparticleLymph NodesImmuneBaseImmunizationIn VitroMalignant NeoplasmsHiv VaccineProteinsEngineeringB-LymphocytesNeutralizing AntibodyTumor

Grant awards (129)

Design of single-shot sequential immunization regimens for HIV using atomic layer deposition technology.$3,017,032

R01 · FY2025 · AI · contact PI

Immune engineering of optimized sequential immunization strategies for HIV vaccines$1,687,928

R33 · FY2025 · AI · contact PI

Predictive drivers of new onset, relapse, and progression of human autoimmunity in skin$1,248,082

U01 · FY2025 · AI

Maximizing germinal centers and somatic hypermutation to HIV Env immunogens$874,385

R37 · FY2025 · AI

Integration of adjuvant derived nanoparticles and engineered mRNA for HIV vaccine discovery$729,905

R01 · FY2025 · AI

Immunotherapy via engineered therapeutic programs in tumors using RNA$639,680

U01 · FY2025 · CA

"Extended dosing" immunization to enhance humoral immunity to next-generation vaccines$454,147

R01 · FY2025 · AI · contact PI

Delivery of cytokines for cancer immunotherapy using nanolayer-controlled trafficking of liposomal nanoparticles$353,924

R01 · FY2025 · CA

Microscopy$312,920

P30 · FY2025 · CA · contact PI

Cancer Research CareerEnhancement and Related Activities$312,919

P30 · FY2025 · CA · contact PI

Predictive drivers of new onset, relapse, and progression of human autoimmunity in skin$1,248,082

U01 · FY2024 · AI

Maximizing germinal centers and somatic hypermutation to HIV Env immunogens$882,023

R37 · FY2024 · AI

Immune engineering of optimized sequential immunization strategies for HIV vaccines$810,280

R33 · FY2024 · AI · contact PI

Integration of adjuvant derived nanoparticles and engineered mRNA for HIV vaccine discovery$751,497

R01 · FY2024 · AI

Immunotherapy via engineered therapeutic programs in tumors using RNA$607,159

U01 · FY2024 · CA

Localized immunotherapy using alum-binding therapeutics$505,710

R01 · FY2024 · EB · contact PI

Predictive drivers of new onset, relapse, and progression of human autoimmunity in skin$476,100

U01 · FY2024 · AI

"Extended dosing" immunization to enhance humoral immunity to next-generation vaccines$469,443

R01 · FY2024 · AI · contact PI

Investigation of Synthetic DNA-based Viral Particles for Spatially Controlled Antigen Presentation$387,750

R01 · FY2024 · AI

Enhancing CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor$321,825

R01 · FY2024 · CA · contact PI

Microscopy$201,563

P30 · FY2024 · CA · contact PI

Cancer Research CareerEnhancement and Related Activities$123,643

P30 · FY2024 · CA · contact PI

Integration of adjuvant derived nanoparticles and engineered mRNA for HIV vaccine discovery$62,718

R01 · FY2024 · AI

Predictive drivers of new onset, relapse, and progression of human autoimmunity in skin$1,264,957

U01 · FY2023 · AI

Maximizing germinal centers and somatic hypermutation to HIV Env immunogens$869,654

R37 · FY2023 · AI

Immune engineering of optimized sequential immunization strategies for HIV vaccines$779,142

R61 · FY2023 · AI · contact PI

Integration of adjuvant derived nanoparticles and engineered mRNA for HIV vaccine discovery$778,064

R01 · FY2023 · AI

Targeted delivery of cytopathicity enhancing agents, and co-ordination with shock and kill, to reduce HIV reservoirs$763,694

R01 · FY2023 · AI

Immunotherapy via engineered therapeutic programs in tumors using RNA$626,885

U01 · FY2023 · CA

Localized immunotherapy using alum-binding therapeutics$518,397

R01 · FY2023 · EB · contact PI

"Extended dosing" immunization to enhance humoral immunity to next-generation vaccines$469,443

R01 · FY2023 · AI · contact PI

Investigation of Synthetic DNA-based Viral Particles for Spatially Controlled Antigen Presentation$387,750

R01 · FY2023 · AI

Enhancing CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor$331,987

R01 · FY2023 · CA · contact PI

Delivery of cytokines for cancer immunotherapy using nanolayer-controlled trafficking of liposomal nanoparticles$315,363

R01 · FY2023 · CA

Microscopy$201,563

P30 · FY2023 · CA · contact PI

Cancer Research CareerEnhancement and Related Activities$123,643

P30 · FY2023 · CA · contact PI

2023 Cancer Nanotechnology Gordon Research Conference and Gordon Research Seminar$5,000

R13 · FY2023 · CA · contact PI

Maximizing germinal centers and somatic hypermutation to HIV Env immunogens$883,119

R37 · FY2022 · AI

Immune engineering of optimized sequential immunization strategies for HIV vaccines$779,142

R61 · FY2022 · AI · contact PI

Targeted delivery of cytopathicity enhancing agents, and co-ordination with shock and kill, to reduce HIV reservoirs$774,058

R01 · FY2022 · AI

Immunotherapy via engineered therapeutic programs in tumors using RNA$626,885

U01 · FY2022 · CA

Localized immunotherapy using alum-binding therapeutics$520,695

R01 · FY2022 · EB · contact PI

Investigation of Synthetic DNA-based Viral Particles for Spatially Controlled Antigen Presentation$387,750

R01 · FY2022 · AI

Enhancing CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor$331,987

R01 · FY2022 · CA · contact PI

Delivery of cytokines for cancer immunotherapy using nanolayer-controlled trafficking of liposomal nanoparticles$315,363

R01 · FY2022 · CA

Microscopy$201,563

P30 · FY2022 · CA · contact PI

Cancer Research CareerEnhancement and Related Activities$123,643

P30 · FY2022 · CA · contact PI

Maximizing germinal centers and somatic hypermutation to HIV Env immunogens$922,142

R37 · FY2021 · AI

Immune engineering of optimized sequential immunization strategies for HIV vaccines$790,753

R61 · FY2021 · AI · contact PI

Targeted delivery of cytopathicity enhancing agents, and co-ordination with shock and kill, to reduce HIV reservoirs$784,154

R01 · FY2021 · AI

SpongeBot: genetically engineered cells to suppress SARS-CoV-2 and future viruses$752,435

R01 · FY2021 · EB · contact PI

Immunotherapy via engineered therapeutic programs in tumors using RNA$653,455

U01 · FY2021 · CA

Localized immunotherapy using alum-binding therapeutics$522,925

R01 · FY2021 · EB · contact PI

Synthetic biology-regulated RNA vaccines$500,599

R01 · FY2021 · EB · contact PI

Investigation of Synthetic DNA-based Viral Particles for Spatially Controlled Antigen Presentation$387,750

R01 · FY2021 · AI

Enhancing CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor$340,336

R01 · FY2021 · CA · contact PI

Delivery of cytokines for cancer immunotherapy using nanolayer-controlled trafficking of liposomal nanoparticles$321,799

R01 · FY2021 · CA

Microscopy$201,563

P30 · FY2021 · CA · contact PI

Maximizing germinal centers and somatic hypermutation to HIV Env immunogens$841,574

R01 · FY2020 · AI

Targeted delivery of cytopathicity enhancing agents, and co-ordination with shock and kill, to reduce HIV reservoirs$793,988

R01 · FY2020 · AI

Synthetic biology-regulated RNA vaccines$511,695

R01 · FY2020 · EB · contact PI

Lymph node-targeted molecular vaccines for mucosal HIV immunity$395,744

P01 · FY2020 · AI · contact PI

Enhancing CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor$348,609

R01 · FY2020 · CA · contact PI

Delivery of cytokines for cancer immunotherapy using nanolayer-controlled trafficking of liposomal nanoparticles$321,799

R01 · FY2020 · CA

Biomaterials and Nanovaccines$294,448

P01 · FY2020 · AI · contact PI

Microscopy$201,563

P30 · FY2020 · CA · contact PI

Targeted delivery of cytopathicity enhancing agents, and co-ordination with shock and kill, to reduce HIV reservoirs$838,922

R01 · FY2019 · AI

Maximizing germinal centers and somatic hypermutation to HIV Env immunogens$834,886

R01 · FY2019 · AI

Synthetic biology-regulated RNA vaccines$509,932

R01 · FY2019 · EB · contact PI

Lymph node-targeted molecular vaccines for mucosal HIV immunity$399,807

P01 · FY2019 · AI · contact PI

Lymph node-targeted molecular vaccines$348,829

R01 · FY2019 · EB · contact PI

Delivery of cytokines for cancer immunotherapy using nanolayer-controlled trafficking of liposomal nanoparticles$321,799

R01 · FY2019 · CA

Biomaterials and Nanovaccines$294,448

P01 · FY2019 · AI · contact PI

2019 Cancer Nanotechnology Gordon Research Conference and Gordon Research Seminar$5,000

R13 · FY2019 · CA · contact PI

Maximizing germinal centers and somatic hypermutation to HIV Env immunogens$841,326

R01 · FY2018 · AI

Synthetic biology-regulated RNA vaccines$510,815

R01 · FY2018 · EB · contact PI

T-cell-mediated targeting of therapeutics to HIV reservoirs$422,887

R01 · FY2018 · AI · contact PI

Lymph node-targeted molecular vaccines$348,263

R01 · FY2018 · EB · contact PI

Biomaterials and Nanovaccines$294,450

P01 · FY2018 · AI · contact PI

Lymph node-targeted molecular vaccines for mucosal HIV immunity$218,510

P01 · FY2018 · AI · contact PI

Maximizing germinal centers and somatic hypermutation to HIV Env immunogens$848,466

R01 · FY2017 · AI

T-cell-mediated targeting of therapeutics to HIV reservoirs$422,887

R01 · FY2017 · AI · contact PI

Lymph node-targeted molecular vaccines for mucosal HIV immunity$367,197

P01 · FY2017 · AI · contact PI

Lymph node-targeted molecular vaccines$347,714

R01 · FY2017 · EB · contact PI

Biomaterials and Nanovaccines$294,282

P01 · FY2017 · AI · contact PI

Targeting immunosuppression blockade to T cells for cancer immunotherapy$279,329

R01 · FY2017 · CA · contact PI

Vaccine Adjuvant/ Delivery Systems Core$216,253

P01 · FY2017 · AI · contact PI

Maximizing germinal centers and somatic hypermutation to HIV Env immunogens$936,822

R01 · FY2016 · AI

Lymph node-targeted molecular vaccines for mucosal HIV immunity$545,703

P01 · FY2016 · AI · contact PI

T-cell-mediated targeting of therapeutics to HIV reservoirs$422,887

R01 · FY2016 · AI · contact PI

Biomaterials and Nanovaccines$399,322

P01 · FY2016 · AI · contact PI

Lymph node-targeted molecular vaccines$347,181

R01 · FY2016 · EB · contact PI

Vaccine Adjuvant/ Delivery Systems Core$303,534

P01 · FY2016 · AI · contact PI

Targeting immunosuppression blockade to T cells for cancer immunotherapy$279,900

R01 · FY2016 · CA · contact PI

T-cell-mediated targeting of therapeutics to HIV reservoirs$422,887

R01 · FY2015 · AI · contact PI

Engineered lipid vesicles as potent vaccine vectors for HIV$318,404

R01 · FY2015 · AI · contact PI

Vaccine Adjuvant/ Delivery Systems Core$299,448

P01 · FY2015 · AI · contact PI

Targeting immunosuppression blockade to T cells for cancer immunotherapy$280,445

R01 · FY2015 · CA · contact PI

Lipid-Enveloped Nanoparticle Vaccines for HIV Neutralizing Antibody Generation$269,091

U19 · FY2015 · AI · contact PI

T-cell-mediated targeting of therapeutics to HIV reservoirs$436,887

R01 · FY2014 · AI · contact PI

Lipid-Enveloped Nanoparticle Vaccines for HIV Neutralizing Antibody Generation$321,964

U19 · FY2014 · AI · contact PI

Engineered lipid vesicles as potent vaccine vectors for HIV$319,195

R01 · FY2014 · AI · contact PI

Vaccine Adjuvant/ Delivery Systems Core$307,030

P01 · FY2014 · AI · contact PI

Targeting immunosuppression blockade to T cells for cancer immunotherapy$272,535

R01 · FY2014 · CA · contact PI

Vaccine Adjuvant/ Delivery Systems Core$310,867

P01 · FY2013 · AI · contact PI

Lipid-Enveloped Nanoparticle Vaccines for HIV Neutralizing Antibody Generation$301,279

U19 · FY2013 · AI · contact PI

Engineered lipid vesicles as potent vaccine vectors for HIV$300,750

R01 · FY2013 · AI · contact PI

Targeting immunosuppression blockade to T cells for cancer immunotherapy$281,457

R01 · FY2013 · CA · contact PI

Nanoparticle-mediated support of cancer immunotherapy$274,200

R01 · FY2013 · CA · contact PI

Engineered lipid vesicles as potent vaccine vectors for HIV$320,664

R01 · FY2012 · AI · contact PI

Nanoparticle-mediated support of cancer immunotherapy$292,303

R01 · FY2012 · CA · contact PI

Lipid-Enveloped Nanoparticle Vaccines for HIV Neutralizing Antibody Generation$270,031

U19 · FY2012 · AI · contact PI

Lipid-Enveloped Nanoparticle Vaccines for HIV Neutralizing Antibody Generation$327,273

U19 · FY2011 · AI · contact PI

Engineered lipid vesicles as potent vaccine vectors for HIV$321,347

R01 · FY2011 · AI · contact PI

Nanoparticle-mediated support of cancer immunotherapy$292,876

R01 · FY2011 · CA · contact PI

NANOGELS (LIPOSOME-ENCAPSULATED DNA-GELS)$24,512

P41 · FY2011 · RR · contact PI

Lipid-Enveloped Nanoparticle Vaccines for HIV Neutralizing Antibody Generation$331,080

U19 · FY2010 · AI · contact PI

Nanoparticle-mediated support of cancer immunotherapy$302,496

R01 · FY2010 · CA · contact PI

Nanoparticle-mediated support of cancer immunotherapy$303,031

R01 · FY2009 · CA · contact PI

Dissecting lymphocyte chemotaxis using synthetic chemokine-releasing microspheres$127,624

R01 · FY2009 · EB · contact PI

LIPID-ENVELOPED NANOPARTICLE VACCINES FOR HIV$285,727

P01 · FY2008 · AI · contact PI

Chemokine and antigen-carrying nanoparticle co-delivery for an oral HIV vaccine$192,822

R21 · FY2008 · AI · contact PI

Dissecting lymphocyte chemotaxis using synthetic chemokine-releasing microspheres$134,011

R01 · FY2008 · EB · contact PI

Chemokine and antigen-carrying nanoparticle co-delivery for an oral HIV vaccine$196,312

R21 · FY2007 · AI · contact PI

Dissecting lymphocyte chemotaxis using synthetic chemokine-releasing microspheres$137,306

R01 · FY2007 · EB · contact PI

Imaging Cytokine Transfer at the Immunological Synapse$167,115

R01 · FY2006 · EB · contact PI

Imaging Cytokine Transfer at the Immunological Synapse$171,559

R01 · FY2005 · EB

Vaccine-driven modulation of dendritic cell trafficking$158,600

R21 · FY2005 · AI

Vaccine-driven modulation of dendritic cell trafficking$213,600

R21 · FY2004 · AI